StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen gross-to-Net Sales Deductions — Annual Cash Payments & Credit Utilizations ($M) ($M)

Form 10-K Item 7 MD&A Gross-to-Net Sales Deductions Rollforward

Latest, FY2025
39,782
Period ended Dec 31, 2025
Change on a year earlier
+16.3%
34,212 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGross-to-Net Sales Deductions — Annual Cash Payments & Credit Utilizations ($M) ($M)Year on yearSource
FY2025Dec 31, 202539,782+16.3%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
FY2024Dec 31, 202434,212+17.0%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
FY2023Dec 31, 202329,251+18.9%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
FY2022Dec 31, 202224,606+14.4%Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗
FY2021Dec 31, 202121,514+17.7%Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗
FY2020Dec 31, 202018,279+26.1%Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗
FY2019Dec 31, 201914,497+8.5%Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗
FY2018Dec 31, 201813,363–Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗

Breakdown

What makes up gross-to-net sales deductions — annual cash payments & credit utilizations ($m)

Cite this data

StockData. (2026). Amgen Gross-to-Net Sales Deductions — Annual Cash Payments & Credit Utilizations ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gtn_pay_tot

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.